Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Natural killer (NK) cells possess inherent tumor-killing capabilities, making them attractive for cancer immunotherapy.
• Chimeric antigen receptor (CAR) technology has revolutionized T cell therapy, particularly for hematological malignancies.
• CAR-T cell therapy faces clinical limitations, prompting exploration of alternative CAR-modified immune cells.

Purpose of the Study:

• To evaluate the potential of CAR-NK cell therapy as an alternative to CAR-T cell therapy.
• To highlight the advantages and challenges associated with CAR-NK cell therapy.
• To identify future research directions for optimizing NK cell-based immunotherapies.

Main Methods:

• Review of preclinical and clinical studies on CAR-NK cell therapy.
• Comparison of CAR-NK cell therapy with existing CAR-T cell therapy.
• Analysis of challenges in CAR-NK cell development and application.

Main Results:

• CAR-NK cell therapy demonstrates significant anti-tumor activity in preclinical and clinical settings.
• CAR-NK cell therapy appears to be safer than CAR-T cell therapy.
• Key challenges include in vitro expansion, storage, shipping, and transduction efficiency of NK cells.

Conclusions:

• CAR-NK cell therapy holds substantial promise for cancer treatment due to its direct tumor cell killing and potential safety benefits.
• Overcoming technical hurdles in NK cell manipulation is crucial for clinical translation.
• Further optimization and combination strategies are essential to enhance the efficacy of NK cell-based immunotherapies.